Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.43 |
| ▸ | MAPT | P10636 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10292170 | 0.94 | MAPT (0.40) | TP53MAPTHRH1CYP2D6KCNH2 | |
| SCHEMBL762801 | 0.93 | TP53 (0.41) | TP53MAPTALDH1A1HRH1CYP2D6 | |
| SCHEMBL762671 | 0.89 | TP53 (0.40) | TP53ALDH1A1HRH1CYP2D6KCNH2 | |
| SCHEMBL762803 | 0.88 | HRH1 (0.41) | TP53ALDH1A1HRH1CYP2D6KCNH2 | |
| SCHEMBL762570 | 0.87 | HRH1 (0.42) | TP53ALDH1A1HRH1CYP2D6KCNH2 | |
| SCHEMBL763297 | 0.87 | HRH1 (0.40) | TP53ALDH1A1HRH1CYP2D6KCNH2 | |
| SCHEMBL762679 | 0.87 | HRH1 (0.40) | TP53ALDH1A1HRH1CYP2D6KCNH2 | |
| SCHEMBL10292328 | 0.87 | KCNH2 (0.41) | TP53MAPTHRH1CYP2D6KCNH2 | |
| SCHEMBL763295 | 0.87 | TP53 (0.44) | TP53MAPTALDH1A1HRH1CYP2D6 | |
| SCHEMBL741564 | 0.86 | MAPT (0.41) | TP53MAPTALDH1A1HRH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |